Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;11(21):2923-36.
doi: 10.2217/fon.15.239. Epub 2015 Sep 28.

Recurrence of hepatocellular carcinoma after liver transplantation: an update

Alessandra Mazzola  1   2 , Andrea Costantino  1 , Salvatore Petta  1 , Tommaso Vincenzo Bartolotta  3 , Maurizio Raineri  4 , Rodolfo Sacco  5 , Giuseppe Brancatelli  3 , Calogero Cammà  1 , Giuseppe Cabibbo  1
Affiliations
Review

Recurrence of hepatocellular carcinoma after liver transplantation: an update

Alessandra Mazzola et al. Future Oncol. 2015.

Abstract

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70-85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. The aim of this review is to underline the main concerns, pitfalls and warnings for these patients.

Keywords: hepatocellular carcinoma; immunosuppression; liver transplantation; living donors; recurrence.

PubMed Disclaimer

LinkOut - more resources